Medicinal Mushroom Immunology: Beta-Glucans, NK Cells, and the Clinical Evidence
Last reviewed: 21 Maret 2026, 7.02
Medicinal mushrooms have been used in traditional medicine systems across East Asia for centuries, and modern immunological research has begun to elucidate the specific molecular mechanisms through which fungal compounds interact with the human immune system. The primary immunoactive constituents in medicinal mushrooms are polysaccharides, particularly beta-glucans — complex carbohydrates with distinctive branching structures that vary between species and are recognized by the immune system as pathogen-associated molecular patterns (PAMPs). This recognition occurs primarily through the Dectin-1 receptor on innate immune cells, as well as through complement receptor 3 (CR3) and Toll-like receptors, triggering a cascade of immunomodulatory signaling events. Unlike synthetic immunostimulants, mushroom-derived beta-glucans appear to function as biological response modifiers, meaning they may upregulate immune function when it is suppressed and help normalize it when it is overactive, though this bidirectional activity is better demonstrated in preclinical models than in human trials.
Reishi (Ganoderma lucidum) is one of the most extensively studied medicinal mushrooms, with over 400 bioactive compounds identified including beta-glucans, triterpenoids (ganoderic acids), and small proteins with immunomodulatory properties. Clinical trials of reishi have shown variable results depending on the preparation and population studied. A Cochrane review examining reishi for cancer treatment found limited evidence that reishi could be used as a sole treatment, but noted that when used alongside conventional therapy, reishi supplementation was associated with improved immune cell counts, specifically increases in CD3+, CD4+, and CD8+ T lymphocytes and natural killer cell activity. Several randomized trials in healthy older adults have reported that reishi supplementation may increase natural killer cell cytotoxicity and enhance the production of interleukin-2, a cytokine critical for T cell proliferation. However, these studies have generally been small, and the heterogeneity of reishi preparations used across studies makes it difficult to establish standardized dosing recommendations.
Turkey tail (Trametes versicolor) has garnered particular research interest due to its polysaccharopeptide components PSK (polysaccharide-K, also known as krestin) and PSP (polysaccharopeptide). PSK has been approved as an adjunctive cancer therapy in Japan since the 1970s and has been studied in over 40 clinical trials, making it one of the most clinically validated mushroom compounds. In the context of immune support rather than oncology, a randomized trial published in ISRN Oncology demonstrated that turkey tail supplementation in healthy volunteers increased natural killer cell functional activity and increased counts of CD8+ T cells and CD19+ B cells in a dose-dependent manner. Chaga (Inonotus obliquus) has been less extensively studied in human clinical trials but has shown potent immunomodulatory effects in cell culture and animal models, with its betulinic acid and melanin pigments demonstrating antioxidant and anti-inflammatory properties in addition to the immunostimulatory effects of its beta-glucan content.
The standardization and quality control of medicinal mushroom supplements present significant challenges for both researchers and consumers. Beta-glucan content can vary dramatically between products depending on whether the supplement uses the mushroom fruiting body or the mycelium, the growing substrate, the extraction method, and the drying process. Mycelium-on-grain products, which are grown on rice or oat substrate, may contain substantial amounts of starch that can inflate polysaccharide measurements without contributing meaningful beta-glucan content. Consumers should look for products that specify beta-glucan content measured by validated methods such as the Megazyme assay rather than relying on total polysaccharide claims. Hot water extraction is generally considered essential for liberating beta-glucans from the chitin-rich cell walls of mushrooms, and dual extraction (hot water plus alcohol) captures a broader spectrum of bioactive compounds including the water-insoluble triterpenoids. As research in this field continues to advance, the integration of mushroom immunology with modern clinical trial methodology may help clarify which preparations, doses, and populations are most likely to benefit.
Reishi (Ganoderma lucidum) is one of the most extensively studied medicinal mushrooms, with over 400 bioactive compounds identified including beta-glucans, triterpenoids (ganoderic acids), and small proteins with immunomodulatory properties. Clinical trials of reishi have shown variable results depending on the preparation and population studied. A Cochrane review examining reishi for cancer treatment found limited evidence that reishi could be used as a sole treatment, but noted that when used alongside conventional therapy, reishi supplementation was associated with improved immune cell counts, specifically increases in CD3+, CD4+, and CD8+ T lymphocytes and natural killer cell activity. Several randomized trials in healthy older adults have reported that reishi supplementation may increase natural killer cell cytotoxicity and enhance the production of interleukin-2, a cytokine critical for T cell proliferation. However, these studies have generally been small, and the heterogeneity of reishi preparations used across studies makes it difficult to establish standardized dosing recommendations.
Turkey tail (Trametes versicolor) has garnered particular research interest due to its polysaccharopeptide components PSK (polysaccharide-K, also known as krestin) and PSP (polysaccharopeptide). PSK has been approved as an adjunctive cancer therapy in Japan since the 1970s and has been studied in over 40 clinical trials, making it one of the most clinically validated mushroom compounds. In the context of immune support rather than oncology, a randomized trial published in ISRN Oncology demonstrated that turkey tail supplementation in healthy volunteers increased natural killer cell functional activity and increased counts of CD8+ T cells and CD19+ B cells in a dose-dependent manner. Chaga (Inonotus obliquus) has been less extensively studied in human clinical trials but has shown potent immunomodulatory effects in cell culture and animal models, with its betulinic acid and melanin pigments demonstrating antioxidant and anti-inflammatory properties in addition to the immunostimulatory effects of its beta-glucan content.
The standardization and quality control of medicinal mushroom supplements present significant challenges for both researchers and consumers. Beta-glucan content can vary dramatically between products depending on whether the supplement uses the mushroom fruiting body or the mycelium, the growing substrate, the extraction method, and the drying process. Mycelium-on-grain products, which are grown on rice or oat substrate, may contain substantial amounts of starch that can inflate polysaccharide measurements without contributing meaningful beta-glucan content. Consumers should look for products that specify beta-glucan content measured by validated methods such as the Megazyme assay rather than relying on total polysaccharide claims. Hot water extraction is generally considered essential for liberating beta-glucans from the chitin-rich cell walls of mushrooms, and dual extraction (hot water plus alcohol) captures a broader spectrum of bioactive compounds including the water-insoluble triterpenoids. As research in this field continues to advance, the integration of mushroom immunology with modern clinical trial methodology may help clarify which preparations, doses, and populations are most likely to benefit.